---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-24-000016"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:54:37.020988+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco Q1 revenue $1.205B; adjusted EPS $0.34; FY guidance updated with improved constant currency growth outlook

## Summary
- Q1 revenue $1.205B (-4% reported/CC); reported EPS $0.06, adjusted EPS $0.34; adjusted EBITDA $294M (-22%).
- FY 2024 guidance: revenue $4.46-4.515B (2-3% CC growth), adjusted EBITDA $960M-$1B, adjusted EPS $0.88-$0.96.
- Net leverage 6.1x; expects debt paydown $280-320M in 2024; aqua divestiture closing mid-2024 with proceeds $1.05-1.1B after tax.
- Innovation revenue now expected $375-410M in 2024; three pipeline products (Bovaer, Zenrelia, Credelio Quattro) on track for H2 2024 approval.
- Kexxtone sales paused due to EU CVMP review; expected ~$20M revenue and ~$18M adjusted EBITDA reduction vs Feb guidance.

## SEC filing metadata
- accession: 0001739104-24-000016
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/0001739104-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/elan-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-24-000016
- JSON: https://secwatch.observer/filing/0001739104-24-000016.json
- Plain text: https://secwatch.observer/filing/0001739104-24-000016.txt

## Key facts
- Earnings Releases
  Elanco Animal Health Inc reported the first quarter of 2024 results: revenue $1,205 million, net income $32 million, EPS $0.06. Guidance reaffirmed.
  - Period: the first quarter of 2024
  - Revenue: $1,205 million
  - Net income: $32 million
  - EPS: $0.06
  - Guidance: reaffirmed
  - Result: reported results
  source text: Elanco Animal Health Reports First Quarter 2024 Results • First Quarter 2024 Financial Results ◦ Revenue of $1,205 million ◦ Reported Net income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/0001739104-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.